Penumbra recalls a stroke-clot catheter that can fracture during use

Penumbra is recalling a catheter used in one of the most time-pressured procedures in medicine: pulling a blood clot out of the brain during an acute ischaemic stroke. The Food and Drug Administration recorded the action in its device enforcement database on 7 October 2026, under recall number Z-3331-2026 [s1]. The stated reason is blunt: because of manufacturing issues, the reperfusion catheters may fracture [s1].

What is affected

The recall covers the RED 62 Reperfusion Catheter, a component of the Penumbra System, listed under model and catalogue number THNDRRED62SKIT [s1]. The enforcement record names a single affected lot, H00007856, identified by the device identifier 00815948024359 [s1]. Forty-three units are involved, distributed across the United States — the record lists Alabama, California, Colorado, Florida, Louisiana, North Carolina, New York, Texas, Utah and Wisconsin [s1]. Penumbra began the recall itself on 24 July 2026, making this a voluntary, firm-initiated action rather than one ordered by the agency, and the enforcement record lists its status as ongoing [s1].

The device itself is long established. The RED 62 catheter was cleared through the FDA's 510(k) pathway in 2021, under clearance K203440, as part of the Penumbra System line of neurovascular aspiration catheters [s2]. The recall concerns a manufacturing defect in specific product, not a question about the design that was cleared.

Why a catheter fracture matters

A reperfusion, or aspiration, catheter is threaded from an artery in the groin or wrist all the way up into the vessels of the brain, where it is used to suck out or capture the clot blocking blood flow. Mechanical thrombectomy of this kind is done against the clock, because brain tissue dies quickly once its blood supply is cut off, and the catheter is working inside small, fragile cerebral arteries.

That is the context in which "may fracture" is serious. If a catheter breaks during the procedure, a fragment can be left behind in the vasculature, the device may have to be retrieved, and the thrombectomy can be delayed or complicated — all in a setting where minutes carry a cost. The enforcement record documents the defect and the potential hazard; it classifies the recall but does not, in the fields published, report that any patient was harmed, and the absence of such a report is not proof that no problem occurred [s1].

How to read it

Two things are worth holding apart. The first is the scope: this is a narrow, lot-specific recall of 43 units traced to one lot, not a withdrawal of the Penumbra System or of reperfusion catheters generally [s1]. The second is the nature of the risk: a device that could fail mid-procedure in the brain is a meaningful safety signal regardless of how many units are involved, which is why a recall of a few dozen catheters still warrants notice.

For the hospitals and neuro-interventional teams that use these catheters, the practical task set by any device recall is the same: check whether the named lot is on the shelf, quarantine any affected stock, and follow the manufacturer's instructions for return or replacement. Those steps sit with institutions, because this is a device handled entirely within a specialist procedure room rather than by patients.

Red flags: this recall concerns hospital equipment, not a product patients use themselves; stroke symptoms — sudden face drooping, arm weakness or difficulty speaking — remain a reason to call emergency services immediately. This article describes an FDA enforcement action and is not medical advice. Questions about a specific procedure or device are for the treating clinicians and the hospital, who can check lot numbers against the agency's record.